Knight Therapeutics logo

Knight Therapeutics(OTC) KHTRF

Market Cap$733.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+35%
5 Year+73%
1 Year+69%
1 Month+8%
$7.47
+3.18%
+0.23Today
Knight Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 7.472026-10-01
Knight Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.04%USD 7.182026-09-24
1 month+8.1%USD 6.912026-09-01
3 month+8.07%USD 6.912026-07-02
Year to date+71.72%USD 4.352025-12-31
1 year+69%USD 4.422025-10-01
3 year+125.68%USD 3.312023-10-02
5 year+73.32%USD 4.312021-10-01
Since inception+35.03%USD 5.532014-04-03

Knight Therapeutics Financials at a Glance

Market Cap

$733.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$547.75M

Net Income (TTM)

CA$14.69M

EPS (TTM)

$0.11

P/E Ratio

68.41

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$7.47

Volume

1,800

Open

$7.38

Previous Close

$7.47

Daily Range

$7.38 - $7.47

52-Week Range

$4.07 - $7.47

Estimated Earnings Date

Nov 5, 2026

KHTRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Knight Therapeutics

Knight Therapeutics Inc. is a specialized pharmaceutical company focused on the development, acquisition, and distribution of a diverse range of pharmaceutical products and medical devices. The company operates primarily in Canada and Latin America, offering innovative treatments for various medical conditions.

Products and Services
  • Offers treatments for cancer, including Nerlynx and Tafasitamab
  • Provides medications for chronic conditions like diabetes and multiple myeloma
  • Engages in financing life science companies and venture capital investments
Growth Outlook
  • Expanding product portfolio with new therapeutic options in oncology
  • Strong market presence in Canada and Latin America supports growth potential
  • Investment in research and development to drive innovation and market expansion
Financial Highlights
  • Recent quarterly revenue of CAD 144.2 million, showing resilience
  • Trailing twelve months (TTM) gross profit margin of 36.9%, indicating operational efficiency
  • Current ratio of 2.28, reflecting strong liquidity position
Knight Therapeutics Inc. has established itself as a key player in the pharmaceutical industry, with a focus on specialized treatments that address significant medical needs. The company's diverse product offerings, including treatments for various cancers and chronic conditions, position it well for future growth. The recent quarterly revenue demonstrates the company's ability to generate substantial income, while the gross profit margin indicates effective cost management. Furthermore, a strong current ratio suggests that Knight Therapeutics maintains a solid liquidity position, allowing for continued investment in research and development. Overall, the company's strategic focus on innovation and market expansion presents a compelling opportunity for potential investors.
AI Generated • Sep 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

830

CEO

Samira Sakhia, MBA

Website

www.gud-knight.com

Headquarters

Montreal, QC H4M 2P2, CA

KHTRF Financials

Key Financial Metrics (TTM)

Gross Margin

36.88%

Operating Margin

4.82%

Net Income Margin

2.72%

Return on Equity

1.91%

Return on Capital

-0.26%

Return on Assets

1.42%

Earnings Yield

1.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$733.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.23M

Volume

1.80K

Avg. Volume

4.74K

Financials (TTM)

Gross Profit

CA$215.46M

Operating Income

CA$26.42M

EBITDA

CA$81.38M

Operating Cash Flow

CA$114.92M

Capital Expenditure

-CA$4.87M

Free Cash Flow

CA$110.05M

Cash & ST Invst.

CA$121.17M

Total Debt

CA$34.28M

Knight Therapeutics Performance Analysis

Knight Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 225,496,18916.1%
20232023-12-31CAD 243,166,7557.8%
20242024-12-31CAD 271,032,41811.5%
20252025-12-31CAD 322,115,28218.8%
Knight Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.4%
Q42025-12-319.3%
Q12026-03-3111.9%
Q22026-06-30-3.1%
Knight Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.20N/A
20232023-12-31CAD -0.12-41.9%
20242024-12-31CAD 0.03N/A
20252025-12-31CAD -0.04N/A
Knight Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3070.7%
Q42025-12-31334.1%
Q12026-03-3145.7%
Q22026-06-30-126.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$144.21M

+34.3%

Gross Profit

CA$69.62M

+55.3%

Gross Margin

48.27%

N/A

Market Cap

$733.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$884.08K

N/A

Employees

830

N/A

Net Income

-CA$3.36M

+73.4%

EBITDA

CA$15.03M

+1468.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$121.17M

+4.1%

Total Debt

CA$34.28M

-67.3%

Accounts Receivable

CA$125.82M

+16.8%

Inventory

CA$144.57M

-2.7%

Long Term Debt

CA$14.56M

-82.4%

Short Term Debt

CA$19.72M

-11.2%

Return on Assets

1.42%

N/A

Return on Invested Capital

3.06%

N/A

Free Cash Flow

CA$28.90M

+692.7%

Operating Cash Flow

CA$29.52M

+45.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGYTFAllergy Therapeutics plc
$0.15+0.00%
VRNOFVerano Holdings Corp.
$1.30+8.33%
PTCHFPureTech Health plc
$1.54+0.00%
VHIBFVitalhub Corp.
$5.28+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About KHTRF

What is the current price of Knight Therapeutics?

Knight Therapeutics is trading at $7.47 per share.

What is the 52-week range for Knight Therapeutics?

Over the past 52 weeks, Knight Therapeutics has traded between $4.07 and $7.47.

How much debt does Knight Therapeutics have?

As of the most recent reporting period, Knight Therapeutics reported total debt of CA$24.16M.

How much cash does Knight Therapeutics have on hand?

Knight Therapeutics reported CA$65.93M in cash and cash equivalents in its most recent financial results.

What is Knight Therapeutics’s dividend yield?

Knight Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services